Alternative biomanufacturing platforms succeed not by trying to universally replace the industry-standard CHO cells, but by identifying and dominating specific niches where CHO has weaknesses—such as cost, speed, or intrinsic product quality for certain molecules.
Unlike manufacturing with clonal cell populations, using individual silkworm pupae introduces inherent biological variability between organisms. This creates a significant and scientifically unsolved quality assurance problem for meeting the strict batch-to-batch consistency required for human injectable drugs at commercial scale.
A critical, non-obvious advantage for the Moss platform is the European Medicines Agency's decision to waive human viral testing requirements. This unique regulatory concession provides a significant competitive edge in cost and development timelines for human injectable products, a benefit CHO cells cannot offer.
Medicago's plant-derived COVID-19 vaccine, Covifense, gained full regulatory approval but was discontinued due to its parent company's tobacco industry ties. This case proves a biomanufacturing platform can be technically and regulatorily sound, yet still fail due to external political or corporate structural issues.